Perbandingan Efektivitas Sitikolin dan Pirasetam dalam Peningkatan Skor Glasgow Coma Scale (GCS) pada Pasien Stroke Iskemik di RSUD H. Boejasin Pelaihari
DOI:
https://doi.org/10.28932/jmh.v7i2.10379Keywords:
sitikolin, pirasetam, stroke iskemik, Glasgow Coma Scale, GCSAbstract
Stroke iskemik merupakan salah satu penyebab utama kecacatan neurologis yang memerlukan intervensi farmakologis yang tepat. Sitikolin dan pirasetam merupakan agen neuroprotektif yang umum digunakan dalam praktik klinis, namun perbandingan efektivitas keduanya masih menjadi perdebatan. Penelitian ini bertujuan untuk membandingkan efektivitas kedua obat tersebut terhadap perbaikan fungsi neurologis pasien stroke iskemik, yang dinilai berdasarkan perubahan skor Glasgow Coma Scale (GCS). Desain penelitian yang digunakan adalah deskriptif non-eksperimental dengan pendekatan potong lintang dan data retrospektif. Sebanyak 57 pasien memenuhi kriteria inklusi dan dibagi menjadi dua kelompok, yaitu kelompok yang menerima sitikolin (n=29) dan kelompok yang menerima pirasetam (n=28). Kedua terapi diberikan secara terpisah dengan dosis sitikolin 500–1.000 mg/hari dan pirasetam 4,8–9,6 g/hari selama 7–14 hari perawatan. Analisis statistik menunjukkan peningkatan skor GCS yang signifikan setelah terapi, baik pada kelompok sitikolin (rerata skor 10,5 menjadi 12,8; p<0,001) maupun pada kelompok pirasetam (rerata skor 10,7 menjadi 12,6; p=0,027). Namun, uji Mann–Whitney tidak menunjukkan perbedaan efektivitas yang bermakna antara kedua kelompok (p=0,821). Temuan ini menunjukkan bahwa sitikolin dan pirasetam sama-sama efektif dalam meningkatkan fungsi neurologis pada pasien stroke iskemik, dan keduanya dapat digunakan secara setara berdasarkan pertimbangan klinis dan ketersediaan obat.Downloads
References
Campbell BCV, Khatri P. Ischaemic stroke. Nat Rev Dis Primers. 2020;6(1):70.
Athar I, Malik AM, Khattak NN, Anis A, Iqbal M, Majid H, et al. Reliability of Siriraj stroke score to distinguish between hemorrhagic and ischemic stroke. Brain Hemorr. 2023;13:13-6.
World Health Organization. Global Health Estimates: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2019. Geneva: WHO; 2020.
GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):439–58.
Kementerian Kesehatan RI. Profil Kesehatan Indonesia Tahun 2021. Jakarta: Kemenkes RI; 2022.
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344–e418.
Fatihah AZ. Study the description of neurotherapy in ischemic stroke patients. J Media Komunikasi Ilmu Kesehatan. 2023;15(2):64–71.
Secades JJ, Gareri P. Citicolina: revision farmacologica y clínica, actualizacion 2022. Rev Neurol. 2022;75(Supl 5):S1-89.
Jasielski P, Piedel F, Piwek M, Rocka A, Petit V, Rejdak K. Application of citicoline in neurological disorders: A systematic review. Nutrients. 2020;12(10):3113.
Fouad AA, Al-Mulhim FM, Jresat I. Piracetam as a Therapeutic Agent for Doxorubicin-Induced Cognitive Deficits by Enhancing Cholinergic Functions and Reducing Neuronal Inflammation, Apoptosis, and Oxidative Stress in Rats [Internet]. In: Molecules. Basel (Switzerland): MDPI; 2020;25(13)
Dobryakova YV, Volkova EG, Doronina OA. Piracetam in post-stroke cognitive recovery: a 2022 update. J Stroke Cerebrovasc Dis. 2022;31(11):106482.
Davalos A, Alvarez-Sabin J. Citicoline for acute ischaemic stroke: review of experimental and clinical data. CNS Drugs. 2019;33(6):499–510.
Mijajlovic MD, Pavlovic A, Milic M, Aleksic V, Covickovic Sternic N, Kostic VS. Post-stroke dementia - a comprehensive review. BMC Medicine. 2017;15(1):11.
Shibu A, Meera S, Gopal AV, Gopinath M, Prasobh GR, Raju GN. Comparative study on citicoline vs. citicoline-piracetam in post-stroke. World J Pharm Res. 2023;12(18):639–53.
Prabhakaran S, Smith WS, Torbey MT, Zazulia AR. GCS in prehospital settings: A meta-analysis. Journal of Neurotrauma. 2022;39(5):345-56.
Jain S, Margetis K, Iverson LM. Glasgow Coma Scale [Internet]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. [Cited 2025 Jul 21]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513298/.
Hartanto AS, Basuki A, Juli C. Correlation of Glasgow Coma Scale Score at Hospital Admission with Stroke Hemorrhagic Patient Mortality at Hasan Sadikin Hospital. J. Med Health. 2019;2(4): 938-44
Roy P, Tomassoni D, Nittari G, Traini E, Amenta F. Effects of choline-containing phospholipids on the neurovascular unit: a review. Front Cell Neurosci. 2022;16:988759.
Rimbun S, Anto EJ. Citicoline in acute ischemic stroke: case report. Indones J Med. 2024;9(3):302–9.
Sokolova T, Zakharova OV. Neuroprotective therapy with citicoline and piracetam in acute ischemic stroke. Fabad J Pharm Sci. 2021;46(3):299–310.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Siti N Halisa, Jihan Jihan, Hasan Ismail, Risya Mulyani, Rizka M Miranti
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain the copyright and grant the journal right of first publication with the work
simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
